Podcasts about Epidemiology

Please join my mailing list here

In this foundational episode of Regulated & Relational, Ginger and Julie dive deep into attachment disorders—what they are, how they're diagnosed, and the realities families face when raising children with these challenges.From the history of Reactive Attachment Disorder (RAD) and Disinhibited Social Engagement Disorder (DSED) to the proposed Developmental Trauma Disorder (DTD), Ginger and Julie unpack decades of evolving research, personal experience, and practical tools for caregivers and professionals. They also address the hallmark behaviors—like manipulation, triangulation, lack of empathy—and explore why these behaviors occur, and how to respond in ways that promote healing and connection.This conversation is both honest and hopeful—acknowledging the challenges while sharing effective therapeutic parenting strategies, the importance of pacing and dosing nurture, and the long-term potential for growth and change.The history and evolution of attachment disorder diagnoses in the DSMHow RAD and DSED differ—and why splitting the diagnosis has caused confusionPrevalence rates and why research has been limitedHow attachment disorders can be mistaken for, or co-exist with, autismThe why behind hallmark behaviors:Manipulation and controlTriangulation between adultsLack of cause-and-effect thinkingLow empathyTherapeutic parenting strategies, including:Offering limited, safe choicesMaking implicit care explicitPacing and dosing nurture to build trustReducing chaos and avoiding power strugglesWhy Developmental Trauma Disorder matters—and how it may fill gaps in our understanding of trauma's impact on childrenHopeful outcomes and the critical importance of early intervention and ongoing supportAttachment & Trauma Network: www.attachmenttraumanetwork.orgNational Institute of Health prevalence statistics (2023)Reactive Attachment Disorder - StatPearls - NCBI Bookshelf: https://www.ncbi.nlm.nih.gov/books/NBK537155/ (Published: May 1, 2023)Introduction to children's attachment - NCBI: https://www.ncbi.nlm.nih.gov/books/NBK356196/ https://www.ncbi.nlm.nih.gov/books/NBK537155/#:~:text=Epidemiology,Adolescent%20Well%2DBeing%2C%20No.Research on RAD subtypes: Dr. Charles Zeanah (2004)https://pmc.ncbi.nlm.nih.gov/articles/PMC4342270/ACEs Study: CDC ACEs Resources

A new campaign at UCC aims to make health research more inclusive, to include under-served groups like women, ethnic minorities, LGBTQ+ individuals, older adults, and people with disabilities. Pat hears about it with Frances Shiely, Director of Education and a Professor in patient focused research at the HRB Clinical Research Facility at UCC and a Senior Lecturer in Epidemiology in the School of Public Health.

Dr. John Fleetham chats with Dr. Chris Ryerson and Dr. Yet Khor about their article, "Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease."

Our 50th episode of QuidelOrtho Science Bytes features Dr. Jonathan Temte, a leading public health expert, discussing how schools, families, and healthcare providers can stay ahead of respiratory illnesses this school year. As students return to classrooms, familiar viruses like flu, RSV, and COVID-19 often resurge. Dr. Temte explains why symptoms alone can't reliably distinguish between these illnesses and how rapid diagnostics are essential for early detection, accurate treatment, and preventing further spread.    About Our Speaker:  Dr. Temte joined the Department of Family Medicine and Community Health faculty at the University of Wisconsin-Madison in 1993. He is a professor of family medicine and community health and the Associate Dean for Public Health and Community Engagement for the University of Wisconsin School of Medicine and Public Health. Dr. Temte received his BA from Luther College, an MS in Biological Oceanography from Oregon State University, and his PhD in Zoology and Minor in Epidemiology from the University of Wisconsin. He pursued his medical training at the University of Wisconsin Medical School, where he received his MD. Dr. Temte also served as the Director of the Wisconsin Research and Education Network from 2000 to 2005. He chaired the American Academy of Family Physicians Commission on Science in 2008, the AAFP, and he currently chairs the Wisconsin Council on Immunization Practices. He also served as AAFP liaison to the Advisory Committee on Immunization Practices from 2004 to 2008, where he was appointed a voting member from 2008 to 2015 and served as chair from 2012 to 2015. Dr. Temte has also been active on pandemic influenza and bioterrorism working groups for the state of Wisconsin. In addition to his outstanding credentials, Dr. Temte's research interests include respiratory viruses, influenza, COVID-19, schools, and immunization policy.

Send us a textIn this episode of PTs Snacks podcast, we dive into Whiplash Associated Disorder (WAD). Listeners will learn about the nature of whiplash, common causes, and the anatomical structures involved. We discusse how to effectively evaluate patients using various screening tools and questionnaires, and emphasizes the importance of differentiating WAD from other cervical spine traumas. The episode covers best practices for treating WAD through a multimodal approach that includes manual therapy, exercise, patient education, and nerve mobilization. Tips for practicing and screening for red flags are provided, along with insights on how to empower patients through education and active management.00:00 Introduction to PTs Snacks Podcast00:20 Understanding Whiplash Associated Disorder (WAD)01:20 Epidemiology and Causes of Whiplash03:41 Clinical Evaluation and Screening for Whiplash06:26 Treatment Approaches for Whiplash10:08 Patient Education and Reassurance11:12 Conclusion and Additional ResourcesSupport the showWhy PT Snacks Podcast?This podcast is your go-to for bite-sized, practical info designed for busy, overwhelmed Physical Therapists and students who want to build confidence in their foundational knowledge without sacrificing life's other priorities. Stay Connected! Never miss an episode—hit follow now! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. Join the email list HERE On Instagram? Find unique content at @dr.kasey.hankins! Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less!(These are affiliate links, but I only recommend Medbridge because it's genuinely valuable.) Optimize Your Patient Care with Tindeq: Get 10% off with code PTSNACKS10: [Tindeq] ...

In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss treatment of OSA. In Part 1 we discussed and overview of OSA, in Part 2 we discussed making the diagnosis will, and Part 4 will look at cases. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Sanjay Patel, M.D, Professor of Medicine, Epidemiology, & Clinical and Translational Science, and Director of the Center for Sleep and Cardiovascular Outcomes Research; Medical Director of the Comprehensive Sleep Disorders Program, University of Pittsburgh Medical Center Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400 Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205

Listen as Danny Moore interviews Charlie Larimer on Epidemiology and Predictive Analytics.  Listen as Charlie gives his insight on applying predictive analytics techniques to determine drivers of health outcomes in differing populations and regions.

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

The Trump administration is trying to restrict access to a substance you might find at your local smoke shop. The FDA in late July announced plans to crack down on 7-OH. Commissioner Marty Makary described it as an opioid that can be more potent than morphine and the agency's pushing to get it classified as a Schedule 1 substance -- like ecstasy or heroin. You may not have heard of 7-OH, but you’ve probably heard of kratom. It’s the substance that 7-OH comes from – and it’s controversial in its own right. Some states have banned kratom. The federal government tried to classify it as a Schedule 1 substance in 2016 but opted not to after getting a wave of pushback. This year Washington state regulators withdrew a proposal to designate kratom as a Schedule 1 substance, saying it didn’t meet the criteria. So for now, you can buy kratom products in the state. We wanted to know more about both kratom and 7-OH, so we checked in with a research professor at the University of Washington for insight. Guest: Caleb Banta-Green, research professor at the University of Washington and director of the Center for Community-Engaged Drug Education, Epidemiology and Research. Related stories: FDA recommends concentrated Kratom be scheduled as illicit substance | The Hill What to know about changes to kratom sold in Seattle | Axios Seattle Kratom & 7-OH: What do we know about use, safety, and overdose risk? | Addictions, Drug & Alcohol Institute (University of Washington) What is 7-OH? Opioid-like product may get banned by FDA | USA TODAY Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes. Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

Dr. John Fleetham chats with Dr. Chris Ryerson and Dr. Yet Khor about their article, "Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease."

Caroline Lewis, health care reporter for WNYC and Gothamist, and Joe Hong, investigative data reporter for WNYC and Gothamist, talk about the ongoing Legionnaires' outbreak in Central Harlem, why New York is a hot spot for the disease, and why city inspections of cooling towers were at a low point ahead of the outbreak.

Pediatric rheumatologist Dr. Pamela Weiss speaks with Michael and his 12 year old daughter Ava about  navigating the challenge of living with psoriasis and psoriatic arthritis together as a family.   Join moderator Kaleigh Welch as she discusses the challenges of living with psoriasis and juvenile psoriatic arthritis (JPsA) from diagnosis, misconceptions about psoriatic disease, to management and treatment with pediatric rheumatologist, Dr. Pamela Weiss from Children's Hospital of Philadelphia, Division of Rheumatology, along with Michael and Ava, whose psoriatic disease is truly a family affair. The intent of this episode is to raise awareness about the complexities and nuances associated with living with psoriasis and psoriatic arthritis as a child or an adult and not letting the disease stop you from doing what you love to do. This episode is sponsored by Amgen. Mike, Ava, and Dr. Weiss were compensated for their time. Timestamps: ·       (0:00) Intro to Psoriasis Uncovered and guest welcome pediatric rheumatologist Dr. Pamela Weiss, Michael and Ava Sayles who both have been diagnosed with psoriasis and psoriatic        arthritis.   ·       (1:28) What the psoriatic disease diagnosis process could be like for children and adults.   ·       (5:34) Misconceptions associated with psoriasis leading to delayed diagnosis of psoriatic arthritis. ·       (7:36) What people misunderstand about plaque psoriasis and psoriatic arthritis. ·       (11:06) Challenges to finding the right treatment while living life with psoriatic disease. ·       (17:24) What drives treatment choices for psoriatic disease in youth. ·       (19:59) Assessing what's most important in reaching treatment goals. ·       (23:57) What the future holds for management of Juvenile Psoriatic Arthritis (JPsA). ·       (26:10) Living with psoriatic disease is challenging but find what's right for you and don't give up on what you love to do. Key Takeaways: ·       Diagnosis of plaque psoriasis and psoriatic arthritis can be challenging given subtleties that can occur in the presentation of the disease in adults and children. ·       There are a variety of treatments that work either alone or in combination to treat plaque psoriasis and psoriatic arthritis with choice of treatment dependent on what is the primary goal for the individual's physical and emotional health. ·       The future is bright as understanding of the disease increases and treatment options expand and become more targeted to more effectively address skin and joint issues associated with psoriatic disease. Guest Bios:   Pamela Weiss, M.D., MSCE, is a pediatric rheumatologist and the Clinical Research Director of the Division of Rheumatology at Children's Hospital of Philadelphia. Dr. Weiss is also the Distinguished Endowed Chair in the Department of Pediatrics. She has advanced training in clinical epidemiology with a focus on early diagnosis, and targeted treatment of children with spondyloarthritis (SpA). Dr. Weiss is also a Professor of Pediatrics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. She is a member of the American Academy of Pediatrics, American College of Rheumatology, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the Spondylitis Association of America, and the SPondyloArthritis Research & Treatment Network (SPARTAN). Michael and Ava Sayles, psoriatic disease is a family affair. Both father and daughter, successfully navigate living with plaque psoriasis and psoriatic arthritis. Michael or Mike was diagnosed in his twenties, and Ava at age 7 and then later on juvenile psoriatic arthritis. She is now 12 years old.  They have experienced issues with diagnosis, and a long journey of finding treatment options that worked for them. Mike found the best solution was establishing a routine or rhythm of treatment around work and school to avoid flare-up's if possible, saying “keeping on top of what you need to do for the psoriasis and the arthritis becomes a big part of your life".  Resources: Our Spot: What is Psoriatic Arthritis  

A quick breakdown of public health jargon in under five minutes. This week's word is at the heart of public health itself: epidemiology.

Watch hol+ by Dr. Taz MD on YouTube: https://www.youtube.com/@DrTazMD/podcastsIf you've ever had questions about childhood vaccine safety, the recommended vaccine schedule, or how to support your child's immune system in a more natural, holistic way, this episode is for you.In this powerful and balanced conversation, Dr. Joel “Gator” Warsh, a board-certified integrative pediatrician, shares his insights on the most common vaccine concerns parents face today.He discusses how he approaches vaccine conversations with parents, how to evaluate the current CDC childhood immunization schedule, and the importance of personalizing healthcare decisions for each child. He also explains how functional medicine and holistic pediatric care can play a role in strengthening children's health, supporting the immune system, and addressing parental concerns in a non-judgmental way.Whether you're looking for answers about vaccine side effects, considering delayed vaccine schedules, or exploring natural alternatives to support pediatric immune health, this episode delivers a research-informed, compassionate, and grounded perspective. We also cover how to reduce shame in health discussions and empower parents with the information they need to make confident decisions.Connect further to Hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+About Dr. Joel “Gator” Warsh:Joel Warsh aka DrJoelGator of the popular parenting Instagram is a Board-Certified Pediatrician in Los Angeles, California who specializes in Parenting, Vaccines, Wellness and Integrative Medicine. He is the author of Between a Shot and Hard Place: Tackling Vaccine Questions with Balance, Data, and Clarity. He grew up in Toronto, Canada and completed a Master's Degree in Epidemiology before earning his medical degree from Thomas Jefferson Medical College.He completed his Pediatric Medicine training at Children's Hospital of Los Angeles and then worked in private practice in Beverly Hills before founding his current practice in Studio City.Dr. Gator has published research in peer-reviewed journals on topics including childhood injuries, obesity and physical activity. He has been featured in numerous documentaries, films, summits, podcasts and articles.Stay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Dr. Warsh:https://www.instagram.com/drjoelgator/https://linktr.ee/drjoelgatorHost & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)00:00 Introduction: The Vaccine Debate01:27 Guest Introduction: Dr. Joel “Gator” Warsh03:34 The Importance of Open Dialogue05:55 Understanding Vaccine Polarization12:01 Historical Context: Vaccine Hesitancy13:12 Vaccine Safety and Reporting20:56 The Influence of Big Pharma24:03 Concerns About Vaccine Overload24:51 Dr. Taz's Personal Story27:03 Research Gaps in Vaccine Safety30:39 Autism and Vaccine Hesitancy45:07 Conclusion and Final Thoughts

Commentary by Dr.  Tze-Fan Chao.

Commentary by Dr. Jian'an Wang.

Send us a textToday's guest is Dr. Oluwole Babatunde. Dr Babtunde, known to many as “Wole” is a physician-scientist, psychiatrist, epidemiologist, author, and deeply faithful servant-leader whose life journey speaks powerfully to rising through adversity and becoming a beacon for others. Dr. Oluwole Babatundi was born and raised in Nigeria, where his life was forever changed by the loss of both his parents at a young age. While those early experiences of grief and uncertainty could have broken him, instead they ignited a deep sense of purpose and faith that drives Dr. Babatundi today. He was a physician in Nigeria and after coming to the United States, he earned a Ph.D. in Epidemiology. Despite the odds, Dr. Babatundi has published over 60 scientific papers and is the Chief Resident in Psychiatry at Prisma Health in South Carolina. His engaging and inspiring new book is titled ““Adapt and Advance: A Faith-Based Step-by-Step Guide to Turning Trials into Triumphs.” (See link to his book:  https://www.amazon.com/dp/B0F8WDDK6W.) Additional information on Dr. Babatunde can be found at: https://oluwolebabatunde.com.  Support the show

EPISODE 571 - Marc Sapir - I'll Fly Away, 40 Stories about Amazing Disabled EldersMarc Sapir, a retired primary care, geriatric, and public health physician, is an essayist and political activist. He was the first Medical Director of the Center for Elders' Independence for disabled elders for 9 years. He also previously worked for United Farm Workers and was a panel member of the Mad as Hell Doctors for Single Payer Health Care. A graduate of Brandeis University (BA) and Stanford Medical School (MD), he also holds a Master's Degree in Public Health (MPH) epidemiology from the University of California, Berkeley.He is the author of five plays and writes fiction, poetry, and music. He recently published a memoir, Deja Vu with Quixotic Delusions of Grandeur (May, 2024), and his writing has been featured in the San Francisco Chronicle, the San Jose Mercury News, the Berkeley Daily Planet, the Palo Alto Times, the Stanford Daily, Journal of the American Medical Association (JAMA), American Journal of Public Health, American Journal of Epidemiology, and more. He lives in Berkeley, CA.I'll Fly AwayStories about Amazing Disabled Elders by Marc SapirI'll Fly Away invites readers to delve into the intimate narratives of 40 extraordinary elders, revealing their profound stories of resilience and the vibrant spirit that often persists in the twilight years. This collection not only highlights the challenges faced by aging individuals but also champions the beauty and dignity of every life story.“A collection of wonderful real-life stories on aging. Dr. Sapir vividly portrays a complex series of human emotions, struggles, and relationships.”—Thomas Irungu MD, MPH, medical director Sentara Health Plans, VA“Could the lives of 40 disabled oldsters in a geriatric program make interesting reading? ‘Interesting' is an understatement. These stories are fascinating.”—Anthony Somkin MD, medical director RotaCare West Contra Costamarcsapir.netSupport the show___https://livingthenextchapter.com/podcast produced by: https://truemediasolutions.ca/Coffee Refills are always appreciated, refill Dave's cup here, and thanks!https://buymeacoffee.com/truemediaca

In episode 53 of Going anti-Viral, Dr George Rutherford joins host Dr Michael Saag to provide an update on emerging infectious diseases. Dr Rutherford is a Professor Emeritus of Epidemiology, Preventive Medicine, Pediatrics and History at the University of California San Francisco and of the Center for Global Strategic Information and Public Health Practice at the UCSF Institute for Global Health Sciences. Dr Rutherford discusses his experience during the early onset of the COVID-19 pandemic and shares lessons learned. Dr Saag and Dr Rutherford also discuss the success of Operation Warp Speed in accelerating the development, manufacture, and distribution of COVID-19 vaccines. They also review new emerging infections like influenza A (H5N1) and arthropod viruses like West Nile, dengue, and chikungunya. Dr Saag and Dr Rutherford review efforts by the federal government to dismantle public health programs and discuss the potential impact of these cuts on future pandemics. 0:00 – Introduction1:05 – Dr Rutherford's experience during the early onset of COVID-19 5:36 – Lessons learned from the COVID-19 pandemic8:30 – The success of Operation Warp Speed10:14 – Review of new emerging infections: H5N1 influenza A and arthropod viruses like West Nile, dengue, and chikungunya17:40 – The impact on public health of misinformation on social media and the recent dismantling of public health programs22:12 – Steps needed to respond to future pandemics and how can public health continue to provide services in the face of budget cuts __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Este episódio tem papel duplo: prestar utilidade pública e reforçar a campanha #TodosPeloPirulla - participe você também, contribuindo para a recuperação do amigo, divulgador científico e youtuber Pirulla: vakinha.com.br/vaquinha/pirullaConfira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.>> OUÇA (59min 59s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br* APOIO: NORDVPNSe você escuta o Naruhodo há algum tempo, sabe que eu trabalho muito remotamente.Isso quer dizer que eu acabo usando muitos wifis públicos. Ou mesmo wifis privados, mas sobre os quais eu não tenho controle. E isso expõe dados meus, tais como senhas, números de cartão de crédito… E até mesmo minha privacidade sobre por onde eu estou navegando.Também quer dizer que, em algumas ocasiões, eu estou num país em que eu não posso acessar o conteúdo que está hospedado em outro país, por algum tipo de restrição técnica.Ou seja: perrengues da vida digital.É pra esses momentos todos que eu uso uma VPN, um serviço que protege sua conexão com a Internet.Mas não qualquer VPN: eu uso a NordVPN. Ela é fácil de instalar. fácil de usar e eu já confio por experiência própria.Por isso te convido a experimentar também a NordVPN com um desconto especial para ouvintes Naruhodo - e, se não ficar satisfeito, pode pedir seu reembolso garantido de 30 dias.É só acessar: https://nordvpn.com/naruhodoNordVPN, a VPN nº 1 de 2025 segundo a TechRadar.*APOIO: INSIDERIlustríssima ouvinte, ilustríssimo ouvinte do Naruhodo,Chegamos mais uma vez no momento INSIDER. E hoje eu quero compartilhar com você uma experiência pessoal.Eu sou relativamente minimalista em meu guarda-roupas: 70% das minhas peças são pretas, 90% delas são lisas.E meu estilo é bem informal: a roupa que eu uso no dia a dia não é tão diferente assim da roupa pra sair.Por isso a INSIDER combinou tanto comigo: ela me proporciona informalidade com sofisticação.Tecido encorpado e cortes modernos, que trazem um caimento perfeito. Peças que eu não preciso passar, que não marcam, que não ficam com mau cheiro - e, principalmente, peças que duram.Estilo despojado, sim, mas sempre com cara de novo. Minha vida fica mais prática e eu fico mais bem vestido.Então, fica aqui meu convite: experimente INSIDER você também e aproveite o desconto de 15% para ouvintes do NARUHODOPara isso, o jeito mais fácil é usar o endereço: creators.insiderstore.com.br/NARUHODOOu clicar no link da descrição deste episódio: o cupom NARUHODO será aplicado automaticamente no carrinho.INSIDER, inteligência em cada escolha.#InsiderStore*REFERÊNCIASVaquinha do Pirulahttps://www.vakinha.com.br/vaquinha/pirullaPathophysiology of Ischemic Strokehttps://link.springer.com/chapter/10.1007/978-981-10-5804-2_4Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trialshttps://pmc.ncbi.nlm.nih.gov/articles/PMC5321490/Cryptogenic stroke: time to determine aetiologyhttps://www.jthjournal.org/article/S1538-7836(22)10551-9/fulltextSummary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular diseasehttps://pmc.ncbi.nlm.nih.gov/articles/PMC3716407/A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organizationhttps://journals.sagepub.com/doi/full/10.1177/17474930231156753Dental Management Considerations for the Cardiac Patienthttps://onlinelibrary.wiley.com/doi/abs/10.1111/scd.70048?casa_token=ttBLDqLWGt0AAAAA%3AO1oMHKDSRIFa3VmyQGU7DdblutxTUbu9ryEvRqBoJLUx8AqJhMBvKcnElH5XY2tE88GU3PdTEp8wEx0tClinical diagnosis of stroke subtypes https://www.uptodate.com/contents/clinical-diagnosis-of-stroke-subtypesWorld Stroke Organization: Global Stroke Fact Sheet 2025https://journals.sagepub.com/doi/full/10.1177/17474930241308142Artificial intelligence in stroke rehabilitation: From acute care to long-term recoveryhttps://www.sciencedirect.com/science/article/pii/S0306452225002180?casa_token=NzPfRaWoZOAAAAAA:GEmB6wj1KbQA8dw79yZOaOAnIy416QI0UpvqQlDrz6cCYDgoT7CQ-xwikHLwD8UkNhLlwLhaf40Air pollution and stroke: Short-term exposure's varying effects on stroke subtypeshttps://www.sciencedirect.com/science/article/pii/S0147651325006323Hyperacute stroke care–What's new?https://journals.sagepub.com/doi/full/10.1177/17474930251348387?casa_token=hH0neB-v_E0AAAAA%3A6C706lwrzHGSeV8xAdAUMNudTMYecSZUOVTxCCKUpUfGN0pv7mezUIUcprlNfTQ8JirCLmi7CKlPDgAdvances in Epidemiology, Outcomes, and Population Science in 2024https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.125.049886Chain mediating effect of frailty and depression between nutrition and quality of life in elderly stroke patients https://www.tandfonline.com/doi/abs/10.1080/13548506.2025.2502843Telemedicine and Post-Acute Care Demands: Evidence from Stroke Patientshttps://aisel.aisnet.org/pacis2025/ishealthcare/ishealthcare/17/The global prevalence of oropharyngeal dysphagia in different populations: a systematic review and meta-analysishttps://link.springer.com/article/10.1186/s12967-022-03380-0Stroke–heart syndrome: clinical presentation and underlying mechanismshttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30336-3/abstractBrain–heart interaction after acute ischemic strokehttps://link.springer.com/article/10.1186/s13054-020-02885-8Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Strokehttps://www.ahajournals.org/doi/full/10.1161/STROKEAHA.121.037316Impact of OSA on cardiovascular events after coronary artery bypass surgeryhttps://pubmed.ncbi.nlm.nih.gov/25612013/Sleep apnea prevalence and severity after coronary revascularization versus no intervention: a systematic review & meta-analysishttps://link.springer.com/article/10.1007/s11325-024-03164-4Obstructive Sleep Apnea and Outcomes in Cardiac Surgery: A Systematic Review with Meta-Analytic Synthesis (PROSPERO CRD420251049574)https://www.mdpi.com/2227-9059/13/7/1579Guidelines for the Prevention of Stroke in Women A Statement for Healthcare Professionals From the American Heart Association/American Stroke Associationhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10152977/Clipe da Música Prevenção Contra o AVC 2017https://www.youtube.com/watch?v=F1GjcMJTdeQNaruhodo #236 - Por que temos dor de cabeça?https://www.youtube.com/watch?v=q8FtXVlSz1INaruhodo #264 - Por que é importante conhecer nosso colesterol?https://www.youtube.com/watch?v=5D3ezsGM_5sNaruhodo #256 - Por que roncamos?https://www.youtube.com/watch?v=SfJH_F2GsI4Naruhodo #162 - Por que acontece o nocaute?https://www.youtube.com/watch?v=_UmiDEjZmfcNaruhodo #163 - O que a anestesia desliga no nosso corpo?https://www.youtube.com/watch?v=6IoMagNybTINaruhodo #217 - Por que algumas pessoas tremem?https://www.youtube.com/watch?v=K7KLyBBnK_Q*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

In this JACC Deep Dive, Editor-in-Chief Harlan M. Krumholz, MD, SM, discusses a large real-world study by Min et al. examining heart failure with improved ejection fraction (HFimpEF) in over 24,000 patients. The study found that while EF improvement is common (30%), true remission is rare and relapse occurs in about 25% of cases—highlighting the need for continued guideline-directed medical therapy (GDMT) even after apparent recovery. Listen to the podcast, find out what reviewers and editors liked about the paper, and get more insight into our dedicated focus issue on heart failure.

Have you ever wondered what happens when a toddler gets into something they definitely shouldn't? Today, Dr. Monica Gray, Dr. Pradip Kamat, and Dr. Rahul Damania discuss the case of an 18-month-old boy who accidentally ingested concentrated bleach, presenting with stridor, drooling, and vomiting. They review the clinical approach to caustic ingestions in children, including airway management, diagnostic workup, and the roles of endoscopy, steroids, and multidisciplinary care. The episode also highlights potential complications such as esophageal strictures and cancer, emphasizes prevention strategies, and provides key takeaways for intensivists managing similar pediatric emergencies. If you're an intensivist or just want to know what to do in a pediatric emergency, don't miss these essential takeaways for managing one of the scariest situations in the ER.Show Highlights:Case study of an 18-month-old boy who ingested concentrated bleachClinical presentation including symptoms like stridor, drooling, and vomitingManagement strategies for caustic ingestions in childrenImportance of airway management and monitoring in cases of caustic ingestionDiagnostic workup including imaging and endoscopyDifferential diagnosis considerations for similar presentations (e.g., button batteries, laundry detergent pods)Mechanism of injury caused by alkaline substances like bleachLong-term complications associated with caustic ingestions, such as esophageal strictures and cancerMultidisciplinary approach to treatment involving various medical specialtiesPrevention strategies to reduce the incidence of accidental caustic ingestions in childrenReferences:American Academy of Pediatrics – Pediatric Care Online: Esophageal Caustic Injury (AAP clinical guidance on caustic ingestions).Fuhrman & Zimmerman's Pediatric Critical Care textbook – Chapters on toxicology and gastrointestinal emergencies (covering caustic injury management and critical care approach).Hoffman RS, et al. “Ingestion of Caustic Substances.” New England Journal of Medicine. 2020; 382(18):1739-1748. A comprehensive review of caustic ingestion injuries and management.Arnold M, Numanoglu A. “Caustic ingestion in children – a review.” Semin Pediatr Surg. 2017;26(2):95-104. Review of epidemiology, pathophysiology, and treatment of caustic injuries in kids.Johnson CM, Brigger MT. “The public health impact of pediatric caustic ingestion injuries.” Arch Otolaryngol Head Neck Surg. 2012;138(12):1111-1115. (Epidemiology study showing declining incidence).Pediatric Critical Care Medicine (PCCM) Journal – various case reports and series on caustic ingestion (for case-based insights), and annual National Poison Data System reports (for statistics on pediatric poisonings).Tringali A, et al. ESGE/ESPGHAN Pediatric GI Endoscopy Guidelines (Endoscopy, 2017) – Includes recommendations for endoscopy timing and steroid use in caustic ingestions.Usta M, et al. “High doses of methylprednisolone in the management of caustic esophageal burns.” Pediatrics. 2014;133(6):E1518-24. (Key study demonstrating steroids benefit in grade 2b injuries).Royal Children's Hospital Melbourne – Clinical Practice Guidelines: Caustic Ingestions (2019) – Practical hospital guidelines emphasizing early intubation for airway threat, endoscopy within 24h, IV PPI, and supportive care.

Dr Bill Nelson talks to Dr Elizabeth Platz about her research studying the causes of cancer over time in large groups and using data to assess future risk.

Guests:Kevin O'Sullivan of The Irish TimesCatherine McGuinness, Science CommunicatorProfessor Naomi Allen, Chief Scientist at UK Biobank and Professor in Epidemiology at the University of Oxford

In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss diagnosis of OSA. In Part 1 we discussed and overview of OSA, Part 3 will discuss treatment options, and Part 4 will look at cases. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Sanjay Patel, M.D, Professor of Medicine, Epidemiology, & Clinical and Translational Science, and Director of the Center for Sleep and Cardiovascular Outcomes Research; Medical Director of the Comprehensive Sleep Disorders Program, University of Pittsburgh Medical Center Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400

In this two-part episode of the Brain & Life Podcast, co-host Dr. Katy Peters is joined by Elizabeth Ansell, founder and director of #NotJustFatigue. #NotJustFatigue is a nonprofit organization shining a light on myalgic encephalomyelitis/chronic fatigue syndrome, also known as ME/CFS, and educates patients, clinicians, and health organizations about the condition. Elizabeth shares how raising awareness, and furthering research really improves the everyday lives of people living with ME/CFS. Dr. Peters is then joined by Dr. W. Ian Lipkin, who is known internationally for his research and is the John Snow Professor of Epidemiology, Professor of Neurology, and Professor of Pathology and Cell Biology at Columbia University Irving Medical Center, Mailman School of Public Health. Dr. Lipkin discusses what's next in ME/CFS research and what the future could hold.   Additional Resources #NotJustFatigue How to Fight Fatigue Understanding the Impact of Invisible Illnesses on Daily Life How Families Are Leading the Charge in Rare Disease Advocacy   Other Brain & Life Podcast Episodes on Similar Topics Rare Thoughts on a Rarer Neurologic Condition Shedding Light and Love on a Rare Genetic Condition with Deborah Vauclare Neurofibromatosis Advocacy and Community Building with the Gilbert Family Foundation We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? Record a voicemail at 612-928-6206 Email us at BLpodcast@brainandlife.org   Social Media: Elizabeth Ansell @notjustfatigue; Dr. W. Ian Lipkin @columbiapublichealth Guests: Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

Diana Stanley, Deputy Editor at The Lancet Respiratory Medicine, is joined by Dr Joan Soriano to discuss a new series on the global epidemiology of respiratory disease, exploring the diagnostic challenges, global trends, and future directions for prevention.Read the full Series:https://www.thelancet.com/series-do/global-epidemiology-chronic-respiratory-disease?dgcid=buzzsprout_icw_podcast_lanrescrd25_lanresContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this solo episode of the Meat Mafia Podcast, Harry explores the growing disconnect between the rise in health research and the decline in real-world health outcomes. He breaks down a simple, actionable framework to reclaim your health—built around rest, real food, movement, community, and purpose. This episode is a challenge to stop waiting for perfect answers and start making meaningful changes, one step at a time. Timestamps: (00:00) Introduction (02:00) Health is simple: rest, real food, clean environment, purpose (04:45) Six pillars of health explained (07:00) Overview of a key obesity study and global trends (10:00) Obesity projections for 2030 and academic disconnect (12:30) Introduction of the SOAR ratio and its meaning (16:00) The health theater and Big Food's role (19:00) Marketing, lobbying, and the cost of inaction (22:00) The 3-phase framework: foundation, refinement, mastery (31:00) Call to action: stop spectating, start living with purpose Check out the original article on Substack where I discuss the idea that we're studying the obesity problem, but not fixing it.1. The Epidemiology of Obesity: A Big Picture2. The Overintellectualization of Health3. The 6 Pillars to Reclaiming Your HealthCheck out Noble Origins- 100% grass-fed beef protein with added collagen, colostrum and organs: we created a clean and simple protein powder with all of the nutrient-dense parts of the cow included. It's great for a post-workout shake to build muscle or for a low calorie treat to burn body fat or for hormonal regulation because the added nutrients from the collagen, colostrum, and organ complex. Use code MAFIA25 for 25% OFF your order!Connect with Brett:InstagramXConnect with Harry:InstagramXConnect with Meat Mafia:Instagram - Meat MafiaX - Meat MafiaYouTube - Meat MafiaConnect with Noble Protein:Website - Noble ProteinX - Noble ProteinInstagram - Noble Protein

LISTENER DISCRETION IS ADVISED. More thoughts on OB Learning 12-leads Paralytic choices ALS for AMS Cash RE, Kaimal AJ, Samuels-Kalow ME, Boggs KM, Swanton MF, Camargo CA Jr. Epidemiology of Emergency Medical Services-Attended out-of-Hospital Deliveries and Complications in the United States. Prehosp Emerg Care. 2024;28(7):890-897. Dexter F, Epstein RH, Wachtel RE, Rosenberg H. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia. Anesth Analg. 2013 Jan;116(1):118-22. Nunnally ME, O'Connor MF, Kordylewski H, Westlake B, Dutton RP. The incidence and risk factors for perioperative cardiac arrest observed in the national anesthesia clinical outcomes registry. Anesth Analg. 2015 Feb;120(2):364-70.

Have you ever wondered what happens when a toddler gets into something they definitely shouldn't? Today, Dr. Monica Gray, Dr. Pradip Kamat, and Dr. Rahul Damania discuss the case of an 18-month-old boy who accidentally ingested concentrated bleach, presenting with stridor, drooling, and vomiting. They review the clinical approach to caustic ingestions in children, including airway management, diagnostic workup, and the roles of endoscopy, steroids, and multidisciplinary care. The episode also highlights potential complications such as esophageal strictures and cancer, emphasizes prevention strategies, and provides key takeaways for intensivists managing similar pediatric emergencies. If you're an intensivist or just want to know what to do in a pediatric emergency, don't miss these essential takeaways for managing one of the scariest situations in the ER.Show Highlights:Case study of an 18-month-old boy who ingested concentrated bleachClinical presentation including symptoms like stridor, drooling, and vomitingManagement strategies for caustic ingestions in childrenImportance of airway management and monitoring in cases of caustic ingestionDiagnostic workup including imaging and endoscopyDifferential diagnosis considerations for similar presentations (e.g., button batteries, laundry detergent pods)Mechanism of injury caused by alkaline substances like bleachLong-term complications associated with caustic ingestions, such as esophageal strictures and cancerMultidisciplinary approach to treatment involving various medical specialtiesPrevention strategies to reduce the incidence of accidental caustic ingestions in childrenReferences:American Academy of Pediatrics – Pediatric Care Online: Esophageal Caustic Injury (AAP clinical guidance on caustic ingestions).Fuhrman & Zimmerman's Pediatric Critical Care textbook – Chapters on toxicology and gastrointestinal emergencies (covering caustic injury management and critical care approach).Hoffman RS, et al. “Ingestion of Caustic Substances.” New England Journal of Medicine. 2020; 382(18):1739-1748. A comprehensive review of caustic ingestion injuries and management.Arnold M, Numanoglu A. “Caustic ingestion in children – a review.” Semin Pediatr Surg. 2017;26(2):95-104. Review of epidemiology, pathophysiology, and treatment of caustic injuries in kids.Johnson CM, Brigger MT. “The public health impact of pediatric caustic ingestion injuries.” Arch Otolaryngol Head Neck Surg. 2012;138(12):1111-1115. (Epidemiology study showing declining incidence).Pediatric Critical Care Medicine (PCCM) Journal – various case reports and series on caustic ingestion (for case-based insights), and annual National Poison Data System reports (for statistics on pediatric poisonings).Tringali A, et al. ESGE/ESPGHAN Pediatric GI Endoscopy Guidelines (Endoscopy, 2017) – Includes recommendations for endoscopy timing and steroid use in caustic ingestions.Usta M, et al. “High doses of methylprednisolone in the management of caustic esophageal burns.” Pediatrics. 2014;133(6):E1518-24. (Key study demonstrating steroids benefit in grade 2b injuries).Royal Children's Hospital Melbourne – Clinical Practice Guidelines: Caustic Ingestions (2019) – Practical hospital guidelines emphasizing early intubation for airway threat, endoscopy within 24h, IV PPI, and supportive care.

About Dean:Dr. Dean Sherzai is a behavioral neurologist and neuroscientist whose entire life has been dedicated to behavioral change models at the community and population level. Dean completed his medical and neurology residencies at Georgetown University, followed by a subsequent fellowship in neurodegenerative diseases at the National Institutes of Health. He then pursued a second fellowship in Dementia and Geriatrics at the University of California, San Diego. He also holds two master's degrees in Advanced Sciences at UCSD and in Epidemiology from Loma Linda University. He has received a PhD in Healthcare Leadership, focused on community empowerment, from Loma Linda University/Andrews University. Additionally, he completed the Executive Leadership Program at Harvard Business School. His vision has always been to revolutionize healthcare by empowering communities to take control of their own health. Dr. Ayesha Sherzai is a vascular neurologist and a research scientist. After completing her residency, she completed a fellowship in vascular neurology and Epidemiology at Columbia University Neurological Institute of New York. Dr. Sherzai is at the tail end of a master's degree in public health in lifestyle epidemiology from Loma Linda University. Knowing the importance of empowering her patients and their communities, she completed an extensive culinary training program in New York and now teaches large populations how to make tasty, easy, and healthy meals for their brain health. They are the authors of two best-selling books, The Alzheimer's Solution (2017, HarperCollins) and The 30 day Alzheimer's Solution (2021, HarperCollins). They are currently leading the largest community-based brain health initiative in the country.

In this two-part episode of the Brain & Life Podcast, co-host Dr. Katy Peters is joined by Elizabeth Ansell, founder and director of #NotJustFatigue. #NotJustFatigue is a nonprofit organization shining a light on myalgic encephalomyelitis/chronic fatigue syndrome, also known as ME/CFS, and educates patients, clinicians, and health organizations about the condition. Elizabeth shares her diagnosis journey and explains why education around ME/CFS is so vital. Dr. Peters is then joined by Dr. W. Ian Lipkin, who is known internationally for his research and is the John Snow Professor of Epidemiology, Professor of Neurology, and Professor of Pathology and Cell Biology at Columbia University Irving Medical Center, Mailman School of Public Health. Dr. Lipkin explains what ME/CFS is and how it differs from other conditions with similar symptoms, like long COVID. Make sure to tune in next week for part two to hear about what's next in ME/CFS research and the importance of care partners.   Additional Resources #NotJustFatigue How to Fight Fatigue Understanding the Impact of Invisible Illnesses on Daily Life How Families Are Leading the Charge in Rare Disease Advocacy   Other Brain & Life Podcast Episodes on Similar Topics Rare Thoughts on a Rarer Neurologic Condition Shedding Light and Love on a Rare Genetic Condition with Deborah Vauclare Neurofibromatosis Advocacy and Community Building with the Gilbert Family Foundation   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? Record a voicemail at 612-928-6206 Email us at BLpodcast@brainandlife.org   Social Media: Elizabeth Ansell @notjustfatigue; Dr. W. Ian Lipkin @columbiapublichealth Guests: Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

In the podcast, Swine Extension Educator Sarah Schieck Boelke speaks with Drs. Kim VanderWaal and Igor Paploski about PRRS virus Classification. Both are faculty members in the University of Minnesota Veterinary Population Medicine department. PRRS virus Classification is basically naming of the PRRS virus according to the genetic sequencing of the virus. Kim and Igor explain how PRRS viruses were classified previously and changes to how they are being classified based on their work.Learn more about PRRS virus classification featured in the podcastSwine Health Information Center fact sheet on the epidemiological insights on the PRRS-Loom Variant webtoolLink to PRRS-Loom Variant webtoolJournal article published in Epidemiology, Volume 10, Issue 2. doi: 10.1128/msphere.00709-24

How do we expand the positive impacts of our buildings? Now is the time. The building sector is looking at a once-in-a-generation opportunity to flip from being a major contributor to both chronic disease and climate disruption to becoming one of the primary solutions. The key is provide training and perspective to the professionals involved. Why is it that so few architects base design decisions on the known health impacts of buildings at both the personal and community levels? Similarly, why is it that the role of buildings as determinants of health and disease in society is so frequently overlooked by epidemiologists and other public health professionals? In this interview Adele Houghton (FAIA, DrPH, LEED AP) explains how architects, developers, real estate teams and community groups can use their role power and agency to improve outcomes at many levels and scales, for the benefit of all involved. While no single building can entirely transform a neighborhood's character or its susceptibility to environmental factors, thoughtful design can enhance the health and well-being of residents and businesses, reducing financial risk and contributing to local policy goals.Adele HoughtonAdele Houghton, FAIA, DrPH, LEED AP, works at the intersection of buildings, public health, and climate change. She is a member of the American Institute of Architects College of Fellows and received a Doctor of Public Health (DrPH) degree from the Harvard T.H. Chan School of Public Health, where she also teaches. Her book, Architectural Epidemiology (Johns Hopkins University Press, 2024), co-authored with Professor Carlos Castillo-Salgado of Johns Hopkins University, proposes a novel method for architectural design: combining neighborhood-scale environmental health data with participatory community engagement to maximize a building's positive ripple effect on community and planetary health.TeamHosted by Kristof IrwinEdited by Nico MignardiProduced by M. Walker

Jody reviews pathophysiology, assessment, and treatment of erectile dysfunction.References:1) Raymond, R.C., & Khera, M. Epidemiology and etiologies of male sexual dysfunction. UpToDate. https://www.uptodate.com/contents/epidemiology-and-etiologies-of-male-sexual-dysfunction2) Khera, M. Evaluation of male sexual dysfunction. UpToDate. https://www.uptodate.com/contents/evaluation-of-male-sexual-dysfunction3) Khera, M. Treatment of male sexual dysfunction. UpToDate. https://www.uptodate.com/contents/treatment-of-male-sexual-dysfunction

00:08 — John Feffer is Director of Foreign Policy in Focus. 00:33 — Art Reingold is the Division Head of Epidemiology and Biostatistics at the UC Berkeley School of Public Health. The post Russia's War in Ukraine; Plus, Corona Calls appeared first on KPFA.

June is Men's Mental Health Awareness Month – a time to raise awareness about the mental health challenges faced by men and boys. In this episode, Dr. Samantha Rosenthal, a professor of Health Science at Johnson & Wales University and adjunct professor of Epidemiology at Brown School of Public Health joins Dr. Chan to talk about why encouraging men to prioritize their well-being and seek help when needed is so important. 

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3027: Christian Finn unpacks the science behind breakfast and weight loss, revealing that skipping breakfast doesn't automatically hinder weight management or help it. Drawing from controlled trials and metabolic research, he highlights that the best approach comes down to personal preference, not outdated nutritional dogma. Read along with the original article(s) here: https://muscleevo.net/skipping-breakfast/ Quotes to ponder: "Epidemiology has consistently associated infrequent breakfast consumption with increased risk of adiposity, diabetes, and cardiovascular disease. Yet, these findings do not infer causality and, critically, are more physically active." "Our simple question was (when it comes to weight loss), does it help to eat breakfast? And the answer seems to be probably not." "The common conception that breakfast may facilitate weight management by ‘kick-starting metabolism' was not evident at all in our results, resting metabolic rate stable within just 11 calories per day." Episode references: American Journal of Clinical Nutrition (Breakfast & Weight Loss): https://academic.oup.com/ajcn/article/100/2/507/4576520 Vanderbilt Breakfast Study (1992): https://pubmed.ncbi.nlm.nih.gov/1550088/ Bath Breakfast Project: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049314/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Emily Riederer is a Data Science Senior Manager at Credit Risk Modeling Capital One. Her website can be found here: https://www.emilyriederer.com/   Follow along on Bluesky: Emily: ‪@emilyriederer.bsky.social‬ Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social  

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3027: Christian Finn unpacks the science behind breakfast and weight loss, revealing that skipping breakfast doesn't automatically hinder weight management or help it. Drawing from controlled trials and metabolic research, he highlights that the best approach comes down to personal preference, not outdated nutritional dogma. Read along with the original article(s) here: https://muscleevo.net/skipping-breakfast/ Quotes to ponder: "Epidemiology has consistently associated infrequent breakfast consumption with increased risk of adiposity, diabetes, and cardiovascular disease. Yet, these findings do not infer causality and, critically, are more physically active." "Our simple question was (when it comes to weight loss), does it help to eat breakfast? And the answer seems to be probably not." "The common conception that breakfast may facilitate weight management by ‘kick-starting metabolism' was not evident at all in our results, resting metabolic rate stable within just 11 calories per day." Episode references: American Journal of Clinical Nutrition (Breakfast & Weight Loss): https://academic.oup.com/ajcn/article/100/2/507/4576520 Vanderbilt Breakfast Study (1992): https://pubmed.ncbi.nlm.nih.gov/1550088/ Bath Breakfast Project: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049314/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Nations that once relied on USAID funding to combat the spread of HIV and AIDS have been impacted by President Trump's cuts to the program. On Today's Show:Jon Cohen, senior correspondent with Science, reports on how countries that suffer high rates of HIV/AIDS are coping now that USAID funding has dried up, and how local governments, especially in places like Lesotho, are attempting to figure out solutions. Plus, Wafaa El-Sadr, MD, director of ICAP at Columbia University, professor of epidemiology and medicine at Columbia Mailman School of Public Health, executive vice president of Columbia Global, and lead of the New York City Preparedness & Response Institute, discusses ICAP's HIV/AIDS treatment under the Trump administration.

Carly Brantner is an assistant professor of Biostatistics & Bioinformatics at Duke University and Duke Clinical Research Institute. Resources from this episode: multicate: R package for estimating conditional average treatment effects across one or more studies using machine learning methods PCORnet® Front Door: Access point for potential investigators, patient groups, and other stakeholders to connect with PCORnet and get support for potential research studies Patient-Centered Outcomes Data Repository (PDOCR): De-identified data from 24 (and counting) PCORI-funded studies Follow along on Bluesky: Carly: @carlybrantner.bsky.social Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social  

The U.S. Health Secretary, RFK Jr., announced he was dismissing all the members of the CDC's vaccine advisory committee.On Today's Show:Katelyn Jetelina, founder and author of the newsletter Your Local Epidemiologist, talks about what RFK Jr. says are his goals, and what the consequences might be.

A Chicago violence prevention program is pairing cognitive behavioral therapy with intensive mentoring and wraparound support to help high-risk teens avoid incarceration.Guests:Nour Abdul-Razzak, Research Associate, University of Chicago Harris School of Public Policy; Research Director, University of Chicago Inclusive Economy LabCharles Branas, Professor and Chair, Department of Epidemiology, Columbia University Mailman School of Public HealthToni Copeland, Director of Student Supports and Violence Prevention Programs, Chicago Public SchoolsJennifer Doleac, Executive Vice President of Criminal Justice, Arnold VenturesJasper Guilbault, Therapist, BrightpointGary Ivory, President and CEO, Youth Advocate ProgramsJulie Noobler, Director of Mental Health and Wellness, BrightpointT-ManLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

At the beginning of May, the National Institutes of Health, part of the Department of Health and Human Services, announced a plan to develop a universal vaccine platform. Think: a single shot for flu or COVID-19 that would last years, maybe a lifetime. The plan—called Generation Gold Standard—has a reported budget of $500 million, and a tight deadline. But will it work? And where does the science on this actually stand? In this live broadcast, Hosts Flora Lichtman and Ira Flatow talk with epidemiologist Michael Osterholm and vaccine researcher Ted Ross.Guests: Michael Osterholm is Director of the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota in Minneapolis, Minnesota.Dr. Ted Ross is the global director of vaccine research at the Cleveland Clinic's Florida Research and Innovation Center in Port St. Lucie, Florida. Transcript will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.